TGCT
MCID: TST021
MIFTS: 63

Testicular Germ Cell Tumor (TGCT)

Categories: Cancer diseases, Fetal diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Testicular Germ Cell Tumor

MalaCards integrated aliases for Testicular Germ Cell Tumor:

Name: Testicular Germ Cell Tumor 58 54 76 13 17 74
Male Germ Cell Tumor 58 76 13 74
Spermatocytic Seminoma 60 76 74
Testicular Teratoma 60 56 17
Testicular Non-Seminomatous Germ Cell Tumor 17 74
Male Germ Cell Tumor, Somatic 58 6
Embryonal Cell Carcinoma 76 74
Endodermal Sinus Tumor 60 76
Yolk Sac Tumor 60 74
Seminoma 76 74
Tgct 58 76
Mgct 58 76
Malignant Testicular Non-Seminomatous Germ Cell Tumor 74
Testicular Non-Dysgerminomatous Germ Cell Tumor 60
Non-Dysgerminomatous Germ Cell Tumor of Testis 60
Testicular Non Seminomatous Germ Cell Tumor 60
Non-Seminomatous Germ Cell Tumor of Testis 60
Testicular Seminomatous Germ Cell Tumor 60
Seminomatous Germ Cell Tumor of Testis 60
Nonseminomatous Germ Cell Tumors 76
Germ Cell Tumor, Nonseminomatous 6
Spermatocytic Seminoma, Somatic 58
Nonseminomatous Germ Cell Tumor 74
Tumor, Germ Cell, Testicular 41
Male Germ Cell Tumor; Mgct 58
Germ Cell Tumors, Somatic 58
Testicular Tumor, Somatic 58
Germ Cell Tumor of Testis 54
Embryonal Carcinoma Cell 17
Teratoma of the Testis 60
Testicular Seminoma 60
Teratoma Testicular 76
Seminoma of Testis 60
Teratoma of Testis 74

Characteristics:

Orphanet epidemiological data:

60
testicular seminomatous germ cell tumor
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe); Age of onset: Adult; Age of death: adult,elderly,young Adult;
non-seminomatous germ cell tumor of testis
Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe);
testicular teratoma
Prevalence: <1/1000000 (Europe);
spermatocytic seminoma
Prevalence: <1/1000000 (Europe); Age of onset: Adolescent,Adult; Age of death: normal life expectancy;

OMIM:

58
Inheritance:
somatic mutation

Miscellaneous:
two subtypes - seminoma and nonseminoma
occasionally germ cell tumor arise from extra gonadal site (e.g., mediastinum, retroperitoneum, pineal gland)
most common cancer in men aged 15-40 years
highest incidence in men of european descent
risk factors for development of tgct - family history, cryptorchidism , testicular feminization , klinefelter syndrome, previous tgct, gonadal dysgenesis


HPO:

33
testicular germ cell tumor:
Inheritance somatic mutation sporadic


Classifications:

Orphanet: 60  
Rare urogenital diseases


Summaries for Testicular Germ Cell Tumor

OMIM : 58 Testicular germ cell tumors (TGCTs) affect 1 in 500 men and are the most common cancer in males aged 15 to 40 in western European populations. The incidence of TGCT rose dramatically during the 20th century. Known risk factors for TGCT include a history of undescended testis (UDT), testicular dysgenesis, infertility, previously diagnosed TGCT, and a family history of the disease. Brothers of men with TGCT have an 8- to 10-fold risk of developing TGCT, whereas the relative risk to fathers and sons is 4-fold. This familial relative risk is much higher than that for most other types of cancer (summary by Rapley et al., 2000). (273300)

MalaCards based summary : Testicular Germ Cell Tumor, also known as male germ cell tumor, is related to seminoma and mixed germ cell tumor. An important gene associated with Testicular Germ Cell Tumor is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Pathways in cancer and MAPK signaling pathway. The drugs Carboplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include testis, bone marrow and kidney, and related phenotypes are abnormality of metabolism/homeostasis and cryptorchidism

UniProtKB/Swiss-Prot : 76 Testicular germ cell tumor: A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.

Related Diseases for Testicular Germ Cell Tumor

Diseases in the Testicular Germ Cell Tumor family:

Testicular Germ Cell Tumor 1

Diseases related to Testicular Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
# Related Disease Score Top Affiliating Genes
1 seminoma 31.4 AFP FGFR3 KIT
2 mixed germ cell tumor 30.9 AFP KIT
3 thymoma, familial 30.6 HRAS KIT
4 intratubular embryonal carcinoma 30.6 AFP KIT
5 germ cell cancer 30.6 AFP KIT KITLG MIR371A SPRY4
6 ovarian serous carcinoma 30.3 MIR145 MIR200C
7 adenocarcinoma 30.2 BRAF FGFR3 HRAS KIT STK11
8 renal cell carcinoma, papillary, 1 30.1 BRAF FGFR3 HRAS KIT
9 gastric adenocarcinoma 30.1 AFP BRAF HRAS KIT
10 transitional cell carcinoma 29.9 BRAF FGFR3 HRAS
11 lung cancer 28.5 BRAF FGFR3 HRAS KIT MIR133B MIR140
12 testicular germ cell tumor 1 12.7
13 extragonadal nonseminomatous germ cell tumor 12.6
14 childhood endodermal sinus tumor 12.6
15 ovarian endodermal sinus tumor 12.6
16 vaginal yolk sac tumor 12.6
17 adult endodermal sinus tumor 12.6
18 childhood ovarian endodermal sinus tumor 12.6
19 pediatric testicular germ cell tumor 12.6
20 mediastinal endodermal sinus tumors 12.5
21 pineal region yolk sac tumor 12.4
22 macrocystic pattern testicular yolk sac tumor 12.4
23 solid pattern testicular yolk sac tumor 12.4
24 glandular-alveolar pattern testicular yolk sac tumor 12.4
25 myxomatous pattern testicular yolk sac tumor 12.4
26 papillary pattern testicular yolk sac tumor 12.4
27 enteric pattern testicular yolk sac tumor 12.4
28 reticular pattern testicular yolk sac tumor 12.4
29 central nervous system endodermal sinus tumor 12.4
30 testicular germ cell tumor non-seminomatous 12.4
31 endodermal sinus pattern testicular yolk sac tumor 12.4
32 polyvesicular vitelline pattern testicular yolk sac tumor 12.4
33 hepatoid pattern testicular yolk sac tumor 12.4
34 testis seminoma 12.3
35 extragonadal seminoma 12.3
36 testicular spermatocytic seminoma 12.3
37 pediatric cns embryonal cell carcinoma 12.3
38 mediastinum seminoma 12.2
39 spermatocytoma 12.1
40 tubular variant testicular seminoma 12.1
41 cribriform variant testicular seminoma 12.1
42 pseudoglandular variant testicular seminoma 12.1
43 testicular germ cell cancer 12.0
44 yolk sac tumor of central nervous system 11.9
45 testicular malignant germ cell cancer 11.4
46 pigmented villonodular synovitis 11.4
47 glandular pattern ovarian yolk sac tumor 11.4
48 hepatoid pattern ovarian yolk sac tumor 11.4
49 polyvesicular vitelline pattern ovarian yolk sac tumor 11.4
50 testicular yolk sac tumor 11.3

Graphical network of the top 20 diseases related to Testicular Germ Cell Tumor:



Diseases related to Testicular Germ Cell Tumor

Symptoms & Phenotypes for Testicular Germ Cell Tumor

Human phenotypes related to Testicular Germ Cell Tumor:

33 (show all 7)
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 33 HP:0001939
2 cryptorchidism 33 HP:0000028
3 azoospermia 33 HP:0000027
4 gonadal dysgenesis 33 HP:0000133
5 teratoma 33 HP:0009792
6 carcinoma 33 HP:0030731
7 choriocarcinoma 33 HP:0100768

Symptoms via clinical synopsis from OMIM:

58
Genitourinary Internal Genitalia Male:
painless testicular mass

Laboratory Abnormalities:
isochromosome 12p (i(12p))
elevated hcg (choriocarcinoma)
elevated afp (endodermal sinus tumor)
elevated hcg or afp or both (embryonal carcinoma)
azoospermia/oligospermia (present at diagnosis)

Neoplasia:
male germ cell tumors (gct), 2 subtypes -
seminoma
nonseminoma (embryonal carcinoma, teratoma, choriocarcinoma, endodermal sinus tumor)

Clinical features from OMIM:

273300

MGI Mouse Phenotypes related to Testicular Germ Cell Tumor:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 craniofacial MP:0005382 9.5 BRAF FGFR3 HRAS KIT KITLG SPRY4
2 neoplasm MP:0002006 9.17 AFP BRAF FGFR3 HRAS KIT KITLG

Drugs & Therapeutics for Testicular Germ Cell Tumor

Drugs for Testicular Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
4
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Vinblastine Approved Phase 3 865-21-4 241903 13342
7
Granisetron Approved, Investigational Phase 3,Not Applicable 109889-09-0 3510
8
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 51-75-2 4033
9
Bleomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 11056-06-7 5360373
10
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
11
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 43805 6857599 5310940 9887054
12
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 135968-09-1
13
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
14
Ofloxacin Approved Phase 3 82419-36-1 4583
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Captopril Approved Phase 3 62571-86-2 44093
17
Ribavirin Approved Phase 3 36791-04-5 37542
18
Palivizumab Approved, Investigational Phase 3 188039-54-5
19
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 22916-47-8 4189
21
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
22
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
23
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
24
Acyclovir Approved Phase 3 59277-89-3 2022
25
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
26
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
27
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
28
Polyestradiol phosphate Approved Phase 3 28014-46-2
29
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
30
Histamine Approved, Investigational Phase 3 51-45-6 774
31
Cyproheptadine Approved Phase 3 129-03-3 2913
32
Mycophenolic acid Approved Phase 3 24280-93-1 446541
33
Calcium Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 7440-70-2 271
34 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
35 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
37
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
38 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
40 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
41 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
43 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Immunologic Factors Phase 3,Phase 1,Phase 2,Not Applicable
45 Serotonin Antagonists Phase 3,Phase 2,Not Applicable
46 Antiemetics Phase 3,Phase 2,Not Applicable
47 Serotonin Agents Phase 3,Phase 2,Not Applicable
48 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
49 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
50 Autonomic Agents Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle Unknown status NCT00589537 Phase 3
2 Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors Unknown status NCT00002566 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;vinblastine sulfate
3 Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status NCT00004219 Phase 3 granisetron hydrochloride;lerisetron
4 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Unknown status NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
5 Combination Chemotherapy in Treating Men With Germ Cell Cancer Unknown status NCT00003643 Phase 2, Phase 3 cisplatin;etoposide;paclitaxel
6 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
7 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Unknown status NCT00274950 Phase 3 carboplatin;cisplatin;etoposide;ifosfamide;vinblastine sulfate
8 Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer Completed NCT00003014 Phase 3 carboplatin
9 Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles Completed NCT00324298 Phase 3 cisplatin;etoposide
10 Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Completed NCT00002596 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
11 Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer Completed NCT00003941 Phase 3 cisplatin;etoposide;ifosfamide
12 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
13 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors Completed NCT00053352 Phase 3 cisplatin;etoposide
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
16 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
17 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
18 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
19 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
20 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
21 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
22 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
23 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
24 Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors Terminated NCT00072215 Phase 3 cisplatin;ifosfamide;paclitaxel;vinblastine
25 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
27 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
28 High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
29 Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
30 Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin Completed NCT00002559 Phase 1, Phase 2 cisplatin;ifosfamide;paclitaxel
31 Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors Completed NCT00301782 Phase 2 carboplatin;cisplatin;etoposide phosphate;vincristine sulfate
32 Arsenic Trioxide in Treating Men With Germ Cell Cancer Completed NCT00036842 Phase 2 arsenic trioxide
33 Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
34 Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors Completed NCT00003518 Phase 2 gemcitabine hydrochloride;paclitaxel
35 Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin Completed NCT00006043 Phase 2 temozolomide
36 Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors Completed NCT00002508 Phase 1, Phase 2 carboplatin;etoposide
37 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Completed NCT00002558 Phase 1, Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
38 Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer Completed NCT00002903 Phase 2 docetaxel
39 Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors Completed NCT00453232 Phase 2 cisplatin;etoposide
40 Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer Completed NCT00002943 Phase 2 carboplatin;cyclophosphamide;etoposide
41 Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Completed NCT00453310 Phase 2 sunitinib malate
42 Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors Completed NCT00070096 Phase 2 ixabepilone
43 Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors Completed NCT00470366 Phase 2 cisplatin;ifosfamide;paclitaxel
44 Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin Completed NCT00423852 Phase 1, Phase 2 carboplatin;ifosfamide;paclitaxel
45 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer Completed NCT00002931 Phase 2 carboplatin;etoposide;ifosfamide;paclitaxel
46 Avelumab in Refractory Testicular Germ Cell Cancer. Completed NCT03403777 Phase 2 Avelumab
47 High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Completed NCT00003173 Phase 2 thiotepa
48 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
49 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
50 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate

Search NIH Clinical Center for Testicular Germ Cell Tumor

Genetic Tests for Testicular Germ Cell Tumor

Anatomical Context for Testicular Germ Cell Tumor

MalaCards organs/tissues related to Testicular Germ Cell Tumor:

42
Testis, Bone Marrow, Kidney, Thyroid, Pineal, Lymph Node, Myeloid

Publications for Testicular Germ Cell Tumor

Articles related to Testicular Germ Cell Tumor:

(show top 50) (show all 274)
# Title Authors Year
1
Cytokeratin 7, inhibin, and p63 in testicular germ cell tumor: superior markers of choriocarcinoma compared to β-human chorionic gonadotropin. ( 30359635 )
2019
2
Is gynecomastia related to the disease characteristics and prognosis in testicular germ cell tumor patients? ( 31063146 )
2019
3
Seminoma component of mixed testicular germ cell tumor shows a higher incidence of loss of heterozygosity than pure-type seminoma. ( 30266250 )
2019
4
Association between male pattern baldness and testicular germ cell tumor: a meta-analysis. ( 30634927 )
2019
5
Spontaneous regression as a 'burned-out' non-seminomatous testicular germ cell tumor: a case report and literature review. ( 30647899 )
2019
6
Testicular germ cell tumor: a comprehensive review. ( 30671589 )
2019
7
Association between androgen receptor gene polymorphisms and testicular germ cell tumor: A systematic review and meta-analysis. ( 30900623 )
2019
8
Comprehensive characterization of cancer-testis genes in testicular germ cell tumor. ( 31070303 )
2019
9
Testicular Germ Cell Tumor Showing Concurrent PNET and Neuroglial Neoplasms With Wide Spectrum of Grades. ( 31091205 )
2019
10
Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )
2018
11
Mature Cystic Teratoma of the Lung With a Somatic-Like Malignant Component in a Patient With Testicular Germ-Cell Tumor. ( 30041955 )
2018
12
Distinct telomere length and molecular signatures in seminoma and non-seminoma of testicular germ cell tumor. ( 29579225 )
2018
13
Cutaneous Presentation of a Testicular Germ Cell Tumor With Seminomatous Differentiation. ( 28452794 )
2018
14
Long-Term Cognitive Functioning in Testicular Germ-Cell Tumor Survivors. ( 29352051 )
2018
15
Increased risk of testis failure in testicular germ cell tumor survivors undergoing radiotherapy. ( 29423028 )
2018
16
Prime evidence for testicular germ cell tumor initiation. ( 29545287 )
2018
17
Characteristics, treatment decisions and outcomes of prepubertal testicular germ cell tumor: A descriptive analysis from a large Chinese center. ( 29705139 )
2018
18
Re: Identification of 19 New Risk Loci and Potential Regulatory Mechanisms Influencing Susceptibility to Testicular Germ Cell Tumor. ( 30227584 )
2018
19
A miR-125b/CSF1-CX3CL1/tumor-associated macrophage recruitment axis controls testicular germ cell tumor growth. ( 30237497 )
2018
20
MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. ( 30321995 )
2018
21
Clinicopathological Significance and Antitumor Effect of MPHOSPH1 in Testicular Germ Cell Tumor. ( 30519350 )
2018
22
Codon-specific translation reprogramming promotes resistance to targeted therapy. ( 29925953 )
2018
23
Novel association of familial testicular germ cell tumor and autosomal dominant polycystic kidney disease with PKD1 mutation. ( 27577987 )
2017
24
Testicular germ cell tumor genomics. ( 27584029 )
2017
25
A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. ( 27754579 )
2017
26
More Cases of Benign Testicular Teratomas are Detected in Adults than in Children. A Clinicopathological Study of 543 Testicular Germ Cell Tumor Cases. ( 27796764 )
2017
27
Plasma Cytokines Correlated With Disease Characteristics, Progression-Free Survival, and Overall Survival in Testicular Germ-Cell Tumor Patients. ( 28237180 )
2017
28
Future of testicular germ cell tumor incidence in the United States: Forecast through 2026. ( 28241106 )
2017
29
Antioxidant enzyme profile and lipid peroxidation products in semen samples of testicular germ cell tumor patients submitted to orchiectomy. ( 28266817 )
2017
30
Mosaic chromosome Y loss and testicular germ cell tumor risk. ( 28275244 )
2017
31
Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. ( 28604728 )
2017
32
Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. ( 28604732 )
2017
33
Editorial Comment: Antioxidant enzyme profile and lipid peroxidation products in semen samples of testicular germ cell tumor patients submitted to orchiectomy. ( 28783265 )
2017
34
Association Between RASSF1A Promoter Methylation and Testicular Germ Cell Tumor: A Meta-analysis and a Cohort Study. ( 28871003 )
2017
35
MGMT and CALCA promoter methylation are associated with poor prognosis in testicular germ cell tumor patients. ( 28881587 )
2017
36
Bilateral methachronous testicular germ cell tumor and testicular microlithiasis in a child: Genetic analysis and insights. A case report. ( 29040905 )
2017
37
Gastrointestinal Involvement of Testicular Germ Cell Tumor: A Case Report and Literature Review. ( 29130004 )
2017
38
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. ( 28854169 )
2017
39
Anxiety and depression in long-term testicular germ cell tumor survivors. ( 26439320 )
2016
40
Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor. ( 26908435 )
2016
41
DNA methyltransferase-3 like protein expression in various histological types of testicular germ cell tumor. ( 26917601 )
2016
42
Right Cardiac Chambers Involvement by a Malignant Testicular Germ Cell Tumor: An Imaging-pathologic Correlation. ( 27017904 )
2016
43
Familial testicular germ cell tumor with bilateral disease. ( 27072274 )
2016
44
Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway. ( 27158395 )
2016
45
Brain Metastases as Presenting Feature in 'Burned Out' Testicular Germ Cell Tumor. ( 27182465 )
2016
46
A rare cause in etiology of left atrial mass: metastatic testicular germ cell tumor. ( 27212979 )
2016
47
Identifying functional cancer-specific miRNA-mRNA interactions in testicular germ cell tumor. ( 27235586 )
2016
48
Impact of Bep or Carboplatin Chemotherapy on Testicular Function and Sperm Nucleus of Subjects with Testicular Germ Cell Tumor. ( 27242529 )
2016
49
Does the Serum Metallothionein Level Reflect the Stage of Testicular Germ Cell Tumor? ( 27255355 )
2016
50
Consumption of alcoholic beverages in adolescence and adulthood and risk of testicular germ cell tumor. ( 27474852 )
2016

Variations for Testicular Germ Cell Tumor

UniProtKB/Swiss-Prot genetic disease variations for Testicular Germ Cell Tumor:

76
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Lys650Glu VAR_004160 rs78311289
2 STK10 p.Lys277Glu VAR_023827 rs757545210
3 STK11 p.Gly163Asp VAR_033140 rs137853078

ClinVar genetic disease variations for Testicular Germ Cell Tumor:

6 (show top 50) (show all 73)
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.499_500insT (p.Ser167Phefs) insertion Pathogenic rs387906350 GRCh37 Chromosome 1, 85733513: 85733513
2 BCL10 NM_003921.4(BCL10): c.499_500insT (p.Ser167Phefs) insertion Pathogenic rs387906350 GRCh38 Chromosome 1, 85267830: 85267830
3 BCL10 NM_003921.4(BCL10): c.172C> G (p.Arg58Gly) single nucleotide variant Pathogenic rs121918314 GRCh37 Chromosome 1, 85736475: 85736475
4 BCL10 NM_003921.4(BCL10): c.172C> G (p.Arg58Gly) single nucleotide variant Pathogenic rs121918314 GRCh38 Chromosome 1, 85270792: 85270792
5 BCL10 NM_003921.5(BCL10): c.172C> T (p.Arg58Ter) single nucleotide variant Pathogenic rs121918314 GRCh37 Chromosome 1, 85736475: 85736475
6 BCL10 NM_003921.5(BCL10): c.172C> T (p.Arg58Ter) single nucleotide variant Pathogenic rs121918314 GRCh38 Chromosome 1, 85270792: 85270792
7 STK11 NM_000455.4(STK11): c.488G> A (p.Gly163Asp) single nucleotide variant Pathogenic rs137853078 GRCh37 Chromosome 19, 1220395: 1220395
8 STK11 NM_000455.4(STK11): c.488G> A (p.Gly163Asp) single nucleotide variant Pathogenic rs137853078 GRCh38 Chromosome 19, 1220396: 1220396
9 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh37 Chromosome 11, 533875: 533875
10 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933406 GRCh38 Chromosome 11, 533875: 533875
11 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
12 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
13 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
14 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 GRCh38 Chromosome 7, 140753336: 140753336
15 BRAF NM_004333.5(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 NCBI36 Chromosome 7, 140099605: 140099605
16 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh37 Chromosome 4, 1806119: 1806119
17 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 GRCh38 Chromosome 4, 1804392: 1804392
18 FGFR3 NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu) single nucleotide variant Pathogenic rs78311289 GRCh37 Chromosome 4, 1807889: 1807889
19 FGFR3 NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu) single nucleotide variant Pathogenic rs78311289 GRCh38 Chromosome 4, 1806162: 1806162
20 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
21 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 GRCh38 Chromosome 4, 1801837: 1801837
22 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh37 Chromosome 4, 1807371: 1807371
23 FGFR3 NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys) single nucleotide variant Pathogenic rs28933068 GRCh38 Chromosome 4, 1805644: 1805644
24 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
25 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841
26 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh37 Chromosome 4, 1803571: 1803571
27 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 GRCh38 Chromosome 4, 1801844: 1801844
28 BCL10 NM_003921.5(BCL10): c.488C> T (p.Thr163Met) single nucleotide variant Pathogenic rs370432633 GRCh37 Chromosome 1, 85733524: 85733524
29 BCL10 NM_003921.5(BCL10): c.488C> T (p.Thr163Met) single nucleotide variant Pathogenic rs370432633 GRCh38 Chromosome 1, 85267841: 85267841
30 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 GRCh37 Chromosome 4, 1807890: 1807890
31 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 GRCh38 Chromosome 4, 1806163: 1806163
32 STK11 NM_000455.4(STK11): c.566C> T (p.Thr189Ile) single nucleotide variant Uncertain significance rs587781515 GRCh37 Chromosome 19, 1220473: 1220473
33 STK11 NM_000455.4(STK11): c.566C> T (p.Thr189Ile) single nucleotide variant Uncertain significance rs587781515 GRCh38 Chromosome 19, 1220474: 1220474
34 STK11 NM_000455.4(STK11): c.464+5G> A single nucleotide variant Uncertain significance rs587781681 GRCh37 Chromosome 19, 1219417: 1219417
35 STK11 NM_000455.4(STK11): c.464+5G> A single nucleotide variant Uncertain significance rs587781681 GRCh38 Chromosome 19, 1219418: 1219418
36 STK11 NM_000455.4(STK11): c.1012G> A (p.Val338Met) single nucleotide variant Uncertain significance rs587782302 GRCh37 Chromosome 19, 1223075: 1223075
37 STK11 NM_000455.4(STK11): c.1012G> A (p.Val338Met) single nucleotide variant Uncertain significance rs587782302 GRCh38 Chromosome 19, 1223076: 1223076
38 STK11 NM_000455.4(STK11): c.632G> A (p.Arg211Gln) single nucleotide variant Uncertain significance rs730881982 GRCh38 Chromosome 19, 1220615: 1220615
39 STK11 NM_000455.4(STK11): c.632G> A (p.Arg211Gln) single nucleotide variant Uncertain significance rs730881982 GRCh37 Chromosome 19, 1220614: 1220614
40 STK11 NM_000455.4(STK11): c.719C> G (p.Ser240Trp) single nucleotide variant Likely pathogenic rs730881976 GRCh38 Chromosome 19, 1220702: 1220702
41 STK11 NM_000455.4(STK11): c.719C> G (p.Ser240Trp) single nucleotide variant Likely pathogenic rs730881976 GRCh37 Chromosome 19, 1220701: 1220701
42 STK11 NM_000455.4(STK11): c.1243C> G (p.Arg415Gly) single nucleotide variant Uncertain significance rs864622448 GRCh38 Chromosome 19, 1226588: 1226588
43 STK11 NM_000455.4(STK11): c.1243C> G (p.Arg415Gly) single nucleotide variant Uncertain significance rs864622448 GRCh37 Chromosome 19, 1226587: 1226587
44 KIT NM_000222.2(KIT): c.200C> G (p.Thr67Ser) single nucleotide variant Uncertain significance rs144933028 GRCh38 Chromosome 4, 54695644: 54695644
45 KIT NM_000222.2(KIT): c.200C> G (p.Thr67Ser) single nucleotide variant Uncertain significance rs144933028 GRCh37 Chromosome 4, 55561810: 55561810
46 KIT NM_000222.2(KIT): c.1553C> T (p.Pro518Leu) single nucleotide variant Uncertain significance rs569408054 GRCh38 Chromosome 4, 54727230: 54727230
47 KIT NM_000222.2(KIT): c.1553C> T (p.Pro518Leu) single nucleotide variant Uncertain significance rs569408054 GRCh37 Chromosome 4, 55593396: 55593396
48 KIT NM_000222.2(KIT): c.2881G> A (p.Gly961Ser) single nucleotide variant Uncertain significance rs773828910 GRCh38 Chromosome 4, 54738507: 54738507
49 KIT NM_000222.2(KIT): c.2881G> A (p.Gly961Ser) single nucleotide variant Uncertain significance rs773828910 GRCh37 Chromosome 4, 55604673: 55604673
50 KIT NM_000222.2(KIT): c.2104C> G (p.Leu702Val) single nucleotide variant Uncertain significance rs768847037 GRCh37 Chromosome 4, 55595614: 55595614

Copy number variations for Testicular Germ Cell Tumor from CNVD:

7 (show all 12)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19332 1 149600000 247249719 Gain Testicular germ cell tumor
2 42821 10 40300000 82000000 Loss Testicular germ cell tumor
3 61421 12 1 132349534 Gain Testicular germ cell tumor
4 89303 15 17000000 76100000 Loss Testicular germ cell tumor
5 121721 18 46400000 76117153 Loss Testicular germ cell tumor
6 146937 2 56300000 230700000 Loss Testicular germ cell tumor
7 180589 4 107900000 191273063 Loss Testicular germ cell tumor
8 206877 6 149100000 170899992 Loss Testicular germ cell tumor
9 226157 7 55086724 55275030 Amplification EGFR Testicular germ cell tumor
10 245111 9 101600000 129300000 Loss Testicular germ cell tumor
11 261703 X 24900000 29400000 Gain Testicular germ cell tumor
12 262543 X 37500000 146900000 Gain Testicular germ cell tumor

Expression for Testicular Germ Cell Tumor

Search GEO for disease gene expression data for Testicular Germ Cell Tumor.

Pathways for Testicular Germ Cell Tumor

GO Terms for Testicular Germ Cell Tumor

Cellular components related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.23 MIR133B MIR140 MIR145 MIR200C MIR302D MIR367

Biological processes related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.93 BRAF FGFR3 KIT STK10 STK11
2 positive regulation of cell proliferation GO:0008284 9.89 FGFR3 HRAS KIT KITLG MIR372
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.76 BRAF FGFR3 HRAS KIT
4 protein heterooligomerization GO:0051291 9.61 BCL10 BRAF HRAS
5 positive regulation of MAP kinase activity GO:0043406 9.58 HRAS KIT KITLG
6 protein autophosphorylation GO:0046777 9.56 FGFR3 KIT STK10 STK11
7 positive regulation of Ras protein signal transduction GO:0046579 9.52 HRAS KITLG
8 embryonic hemopoiesis GO:0035162 9.51 KIT KITLG
9 positive regulation of phospholipase C activity GO:0010863 9.48 HRAS KIT
10 T cell receptor signaling pathway GO:0050852 9.46 BCL10 BRAF HRAS STK11
11 ectopic germ cell programmed cell death GO:0035234 9.37 KIT KITLG
12 MAPK cascade GO:0000165 9.35 BRAF FGFR3 HRAS KIT KITLG
13 myeloid progenitor cell differentiation GO:0002318 9.32 BRAF KIT
14 gene silencing by miRNA GO:0035195 9.23 MIR133B MIR140 MIR145 MIR200C MIR302D MIR367

Molecular functions related to Testicular Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.35 BRAF FGFR3 KIT STK10 STK11
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR133B MIR140 MIR145 MIR200C MIR372

Sources for Testicular Germ Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....